Comparison of the Incidence of Dyskinesia in Parkinson's Disease Who Were Treated With Amantadine or Dopamine Agonist

Seoul National University

Status: Unknown

Conditions: Parkinson's Disease

Study type: Observational

Funder types: Other

Identifiers

NCT01338662

H-1009-057-332

Details and patient eligibility

About

The purpose of this study is to compare the onset time and severity of dyskinesia in amantadine or Dopamine agonist initial treated groups in Parkinson's disease.

Full description

1. Dopamine agonist can delay the risk of dyskinesia by initiating treatment rather than levodopa. Amantadine is typical antidyskinetic drug. There is no data about comparison of risk of dyskinesia in amantadine and dopamine agonist by initiating treatment.
2. Prospective , randomized, open label study compare the onset time and severity of dyskinesia between groups randomized assigned order of amantadine and dopamine agonist

Enrollment: 500 estimated patients

Sex: All

Ages: 30 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 30<age<60
• IPD
• H & Y<3

Exclusion criteria

• previous dopaminergic medication history
• dyskinesia
• Parkinson plus
• clinically significant or unstable medical or surgical condition

Trial design

500 participants in 3 patient groups

Group A-1

Description:

* study enroll number 3n+1 (N=0,1,2...) * initial treatment- amantadine * add levodopa when the patient become to need further treatment.

Group A-2

Description:

* study enroll number 3n+2 (N=0,1,2...) * initial treatment: amantadine * add dopamine agonist when the patient become to need further treatment.

Group B

Description:

* study enroll number 3n+3 (N=0,1,2...) * initial treatment: dopamine agonist * add levodopa when the patient become to need further treatment. but cannot use amantadine